rosnilimab
rosnilimab: developed by 2 companies · 1 clinical trial tracked.
rosnilimab evidence translation
What we can confirm
1 tracked trial
What it means
More than one developer is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about rosnilimab, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (2)
Clinical Trials (1)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis
Primary endpoint: Mean change in modified Mayo Score (mMs) from Baseline to Week 12
InterventionalRandomizedquadruple132 targetStarted 2023-12Completion 2026-0550 sites · Austria, Bulgaria, Canada, Croatia…AnaptysBio, Inc.
Frequently asked questions
Who is developing rosnilimab?
rosnilimab is being developed by ANAPTYSBIO, INC, First Tracks Biotherapeutics, Inc..
How many clinical trials involve rosnilimab?
BioSniper tracks 1 clinical trial involving rosnilimab.